Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Altus dissolved

This article was originally published in The Tan Sheet

Executive Summary

Novartis, Quaker discussing future of products and assets in functional foods joint venture whose operations ceased at end of 2001, Quaker says. The 50/50 joint venture, housed in Quaker's Chicago offices, was formed in February 2000 with initial intent of marketing functional foods targeting health concerns of women, athletes and elderly. In 2001, Altus test-marketed Quaker Take Heart cereals, snack bars, juices in New York state and Women's Individual Nutrition cereals, snack bars, smoothies in Colorado. Novartis says joint venture termination was discussed and agreed upon when PepsiCo acquired Quaker Oats last year. Dissolution also reflects Novartis' move away from functional foods; in February, firm announced plans to divest its health and functional foods unit (1"The Tan Sheet" Feb. 11, 2002, p. 12)...

You may also be interested in...

Novartis Consumer Health Reshuffled, Functional Foods On Sales Block

Novartis is reorganizing its consumer health division by grouping together three businesses - OTC drugs, infant and baby and medical nutrition - and operating animal health and Ciba Vision as separate units, the firm stated during a year-end analysts call Feb. 7

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts